Hypertension and nephrology

[The history of diuretic treatment in Hungary. Part I. Imre Fodor]

RADÓ János

DECEMBER 08, 2012

Hypertension and nephrology - 2012;16(05)

[The diuretic effect of mercurial compounds was discovered in 1920. However, the term of “mercurial diuresis” was created 36 years earlier by Ernő Jendrassik. Imre Fodor published his experiences with the mercurial diuretic, which has been cited by several authors worldwide. The Hungarian pharmaceutical industry also took its part from the production of the mercurial diuretic with Novurit that proved to be an excellent and worldwide well known preparation in the next 40 years. Even Imre Fodor required the repeated administration of mercurial diuresis because of his severe cardiac oedema in the last period of his life. When the drug became ineffective, i.e. developed refractory oedema, he made a “self-experiment” with the administration of ACTH to restore the sensitiveness to the mercurial diuretic on the basis of most recent American literature at that time. His experience has been published by his colleagues just before his death. Imre Fodor was an eminent clinician, a school creating internist who entered his name into the science dealing with the use of diuretics.]

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[Terciary hyperparathyreosis or not? ? You cannot solve it alone: combined treatment in severe osteitis fibrosa cystica]

HERSZÉNYI Eszter, PATÓ Éva, SZALAY László, BÍRÓ Zsolt, György Andrea, DEÁK György

[Phosphate retention, consequential rise of the phosphaturic fibroblast growth factor-23 that decreases the level of calcitriol resulting in hypocalcemia facilitates the development of secondary hyperparathyroidism (sHPT) in chronic kidney disease (CKD). Hyperphosphatemia, hypocalcemia and low calcitriol level result in increasing secretion of parathormone (PTH). While sHPT occures frequently in CKD, the development of therapy-resistant and hypercalcemic tertiary hyperparathyroidism is rare due to current therapeutic approaches. We present the case of a 41 year old, treated schizophrenic, hemodialized male patient with severe osteitis fibrosa cystica, severe hyperparathyroidism (PTH 2500 pg/ml) - considered to be tertiary - and with repeated pathologic fractures. While hospitalized, the patient was under supervised, combined therapy with the vitamin D receptor activator paricalcitol and the calcimimetic cinacalcet that resulted in marked decrease of PTH level to 1589 pg/ml. However, after discharge from the hospital due to the lack of compliance he failed to take his medications and PTH had risen to the initial level. This case demonstrates that severe hyperparathyroidism thought to be therapy resistant responds well to a combination of paricalcitol and cinacalcet however, patient compliance is essential to therapeutic success.]

Hypertension and nephrology

[News of the Hungarian Society of Hypertension]

Hypertension and nephrology

[Treatment of hypertension in chronic kidney disease and in renal failure]

KISS István

[The number of patients with chronic renal disease is growing steadily over the past decade. The reason for this is the increasing number of patients developing diabetes mellitus and hypertension, diseases that have common complication of chronic kidney disease. There is evidence that in chronic kidney disease or end-stage renal disease high blood pressure is more common which has a very complex management. Renal patients were able to participate in a small number of clinical studies, so the evidence base of antihypertensive therapy from these studies is limited. Therefore professional guidelines made with thumbnail analysis are very important, which now appeared as the KDIGO recommendations in November 2012. The author of this quick presentation of the practice undertook to summarize the important messages of this paper.]

Hypertension and nephrology

[Role of ramipril/amlodipine fixed combination in treatment hypertension of patients with chronic kidney disease]

VÁRKONYI Magdolna, SIMONYI Gábor

[Hypertension is an important risk factor of chronic kidney disease (CKD) however CKD can cause hypertension. Untreated CKD may result in renal failure. Hypertension and CKD are important cardiovascular risk factors. Several mechanisms play role in the worsening of renal function. The main pathogenetic factor is the increased activity of the renin-angiotensin-aldosteron system (RAAS) that can result in glomerulosclerosis, destroy of nephrons and proteinuria. In the treatment of hypertension in CKD patients inhibiting RAAS is very important because ACE-inhibitors and angiotensin-receptor blockers provide efficient control not only of blood pressure, but also of proteinuria, an effect associated with improved long-term nephroprotection. Between ACE-inhibitors ramipril has proved nephro- and cardiovascular protection effect. Fix combination therapy of ramipril with amlodipine has a very pronounced blood pressure lowering effect and can improve patient compliance too.]

Hypertension and nephrology

[Association between the genetic polymorphism of heat-shock protein 72 and pediatric kidney diseases]

BÁNKI Nóra Fanni, RUSAI Krisztina, KÁROLY Éva, SZEBENI Bea, VANNAY Ádám, SALLAY Péter, REUSZ György, TULASSAY Tivadar, SZABÓ J. Attila, FEKETE Andrea

[Recurring urinary tract infections (UTI) in childhood may result in chronic- and end-stage-renal-disease (ESRD), which leads to the initiation of dialysis and renal transplantation (NTx). Heat shock protein (HSP) 72 protects the kidney, whereas it refolds destroyed proteins and cells, and helps regenerating the renal tissue. The HSPA1B (1267)G allele is associated with lower HSP72 expression. This study assesses the role of HSPA1B A(1267)G polymorphism using PCR-RFLP in 103 children treated because of recurrent UTI, 26 children after NTx and 235 healthy controls. Clinical data were also evaluated. HSPA1B (1267)GG genotype and HSPA1B (1267)G allele occurred more frequently in the UTI (p=0.0001; CI: 1.378-2.68) and in the NTx (p=0.014; CI: 2.29-187.7) patient group than in the controls group, and were associated with a higher risk for scarring (p=0.012; CI: 0.33-1.00) and renal malformation (p=0.0072; CI: 1.623- 140.6). Our data indicate a relationship between the carrier status of HSPA1B (1267)G allele and the development of recurrent UTI and ESRD, raising further questions about the clinical and therapeutic relevance of these polymorphism.]

All articles in the issue

Related contents

LAM Extra for General Practicioners

[RESISTANT HYPERTENSION - DIFFERENTIAL DIAGNOSIS AND THERAPY]

TISLÉR András

[Hypertension is considered resistant to therapy if the target blood pressure is not achieved despite treatment with three different types of antihypertensive drugs, including a diuretic. Causes of therapy resistance may be grouped into three broad categories: Pseudoresistance can be the result of inadequate blood pressure measurement technique, the “white-coat” effect or the patients’ noncompliance with pharmacological and nonpharmacological medical advices. Evaluation of the measurement technique - including the size of the cuff used - and blood pressure monitoring at home can help identify the causes of pseudoresistance. Secondary resistance comprises drug interactions and concomitant medical conditions that elevate blood pressure or antagonize antihypertensive therapy. In addition, secondary resistance can result from disorders associated with secondary hypertension, among which appropriate screening for hyperaldosteronism as well as for renoparenchymal and renovascular hypertension need special emphasis. Suboptimal therapy is frequently related to subclinical volume overload and the use of inappropriate type or dosing of diuretics. Furthermore, when choosing the optimal drug combination, care should be taken to inhibit the various systems that regulate blood pressure as much as possible. In addition to combining the most frequently used antihypertensive drugs, the use of aldosterone antagonists, vasodilators, nitrates or drugs affecting the central nervous system might help to optimise treatment.]

Clinical Neuroscience

[Adrenocorticotrop hormon therapy in acquired childhood epileptic aphasia]

SZABÓ Léna, NAGY Judit, KÁLMÁNCHEY Rozália

[Although Landau-Kleffner syndrome, a childhood-acquired epileptic aphasia, is frequently studied either the underlying pathophisiology or the optimal therapy remained unknown. In our study we aimed to investigate the efficacy of ACTH therapy in Landau-Kleffner syndrome. We have analysed retrospectively the documentation of five children treated by ACTH, who suffered from Landau-Kleffner syndrome. We studied the longitudinal changes of the four most characteristic sympthoms and signs of the syndrome: epileptiform EEG, speech and behaviour disorders, seizures together with the ACTH regimes. Besides, we analysed the relation between the starting date of the therapy and its efficacy. Before giving ACTH, epileptiform EEG and speech disorders were observed in all the five children, seizures in four of them, behaviour disorders in three of them. In two patients the speech disorder had been persisting for years before. Due to the starting ACTH stosstherapy (20 E/day for onetwo weeks) all the four examined signs disappeared or showed quick softening in all the five children in maximum two weeks. We adjusted long-term low dose maintenance therapy to avoid relapses in the long-term follow-up. Epileptiform EEGs have normalised in one case and have decreased in four cases. Speech disorders have disappeared in two and have softened in three children. Behaviour disorders have cured in 3/4 cases, softened in one case. Seizures have disappeared in all cases. One child is totally asymptomatic, four of them lives with softened symptoms. Analysing our data we found that the earlier the therapy starts, the more effective it is. On the basis of our data ACTH is an effective treatment for Landau-Kleffner syndrome. After giving it for only a short period, relapses often occur, to avoid relapses adjustment of long term low dose maintenance therapy is advisable.]

Hypertension and nephrology

[Diuretikumok hypertoniában - 2010]

BARNA István

[Diuretics (especially thiazide derivatives and indapamide that also has vasodilator efficacy) are considered as first line treatment in hypertension. They are particularly favourable in the treatment of overweight, elderly, isolated systolic hypertensive patients suffering from type 2 diabetes and metabolic syndrome or in mild renal and cardiac insufficiency. They can be ideally combined with other antihypertensive agents (primarily with angiotensin-converting enzyme inhibitors, angiotensin receptor blocking agents és béta-blockers). If hypertension is associated with left ventricular hypertrophy or stroke indapamide is the appropriate choice. In case of left ventricular dysfunction and heart failure thiazide and/or furosemide is the adequate option. Low dose diuretics have no clinically relevant side effects and reduce cardiac mortality to the same extent as other pharmaceutical interventions.]

Hypertension and nephrology

[Water intoxication caused by diuretics]

RADÓ János, KOVÁCS Andrea

[Water metabolism in the organism is regulated very exactly under normal circumstances. Sometimes, however, when the level of the antidiuretic hormone is inappropriately high and fluid consuming is not limited, water intoxication can develop. This is especially paradoxical during treatment with diuretics. Authors observed in a cachectic, potassium wasting, 87-year-old female patient, hyponatremia associated with clinical water intoxication developing in a hot period of summer, during long-term thiazide diuretic (chlorthalidone) treatment administered because of high blood pressure. Diagnosis was based besides the clinical picture on the severe hyponatremia and was supported by the relatively high urine osmolality in the presence of a very low plasma osmolality. Despite treatment of hyponatremia in accordance to the recommandations “overcorrection” occurred and turned into fatal hypernatremia. In the period of low plasma osmolality the patient was treated with intravenous infusions containing isotonic saline supplemented with potassium. When hypertonicity developed hypotonic intravenous infusions were given. Authors discuss the literature of hyponatremia with special reference to the dilemmas of therapy such as “slow” versus “rapid” correction as well as procedures to be done in case of “overcorrection”.]

Lege Artis Medicinae

[Resistant hypertension - differential diagnosis and therapy]

TISLÉR András

[Hypertension is considered resistant to therapy if the target blood pressure is not achieved despite treatment with three different types of antihypertensive drugs, including a diuretic. Causes of therapy resistance may be grouped into three broad categories: Pseudoresistance can be the result of inadequate blood pressure measurement technique, the “white-coat” effect or the patients’ noncompliance with pharmacological and nonpharmacological medical advices. Evaluation of the measurement technique - including the size of the cuff used - and blood pressure monitoring at home can help identify the causes of pseudoresistance. Secondary resistance comprises drug interactions and concomitant medical conditions that elevate blood pressure or antagonize antihypertensive therapy. In addition, secondary resistance can result from disorders associated with secondary hypertension, among which appropriate screening for hyperaldosteronism as well as for renoparenchymal and renovascular hypertension need special emphasis. Suboptimal therapy is frequently related to subclinical volume overload and the use of inappropriate type or dosing of diuretics. Furthermore, when choosing the optimal drug combination, care should be taken to inhibit the various systems that regulate blood pressure as much as possible. In addition to combining the most frequently used antihypertensive drugs, the use of aldosterone antagonists, vasodilators, nitrates or drugs affecting the central nervous system might help to optimise treatment.]